The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of site-specific metastases and clinical complications on outcomes of patients with metastatic renal cell carcinoma (mRCC).
 
Jianbo Wang
No Relationships to Disclose
 
Ning Zhang
No Relationships to Disclose
 
Sharon H. Giordano
No Relationships to Disclose
 
Nizar M. Tannir
Stock and Other Ownership Interests - Amgen; Arcturus Therapeutics; Arcus Biosciences; BioCryst; Corvus Pharmaceuticals; First Trust Amex Biotech (FBT); Johnson & Johnson/Janssen; Merck; Nuvation Bio; Revolution Medicines; Surface Oncology; Vanguard Health Care; Xencor
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Deka Biosciences; Eisai; Exelixis; Intellisphere; Merck Sharp & Dohme; Neoleukin Therapeutics; Oncorena; Ono Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Eisai; Lilly; Merck Sharp & Dohme; Oncorena
Research Funding - Arrowhead Pharmaceuticals (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst)
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; crispr therapeutics; Infinity Pharmaceuticals; Janssen; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca